Full Schedule

Home
Full Schedule

All Days
Cancelled
Fri, Apr 10
Sat, Apr 11
Sun, Apr 12
Mon, Apr 13

Full Schedule

Type here to filter the list

Monday, April 13, 2026
6:30 AM - 12:00 PM AST
Registration & Badge Pickup

6:30 AM - 12:00 PM AST

Registration & Badge Pickup

Location: Lobby

7:00 AM - 11:00 AM AST
Speaker Ready Room

7:00 AM - 11:00 AM AST

Speaker Ready Room

Location: 201B

7:00 AM - 12:00 PM AST
Lactation Room

7:00 AM - 12:00 PM AST

Lactation Room

Location: 202A

7:30 AM - 9:00 AM AST
ISS XV: Show Me the Data®: Evolving Standards and New Frontiers in Ovarian Cancer

7:30 AM - 9:00 AM AST

ISS XV: Show Me the Data®: Evolving Standards and New Frontiers in Ovarian Cancer

Location: Ballroom B

7:30 AM - 9:00 AM AST
ISS XVI: Navigating the Winds of Progress: Plotting a Course for Immunotherapy in Endometrial Cancer

7:30 AM - 9:00 AM AST

ISS XVI: Navigating the Winds of Progress: Plotting a Course for Immunotherapy in Endometrial Cancer

Location: 209

7:30 AM - 9:00 AM AST
ISS XVII: Lynparza Trivia Challenge: How well do you know the Maintenance Therapy Landscape in Advanced Ovarian Cancer?

7:30 AM - 9:00 AM AST

ISS XVII: Lynparza Trivia Challenge: How well do you know the Maintenance Therapy Landscape in Advanced Ovarian Cancer?

Location: 208

9:00 AM - 9:30 AM AST
Transition Break

9:00 AM - 9:30 AM AST

Transition Break

9:30 AM - 10:30 AM AST
Focused Forum IX: Precision Strike, The Rise of ADCs
Moderator: Sharee Umpierre, MD – University of Puerto Rico School of Medicine, University of Puerto Rico Comprehensive Cancer Center
Moderator: Robert Wenham, MD, MS – H. Lee Moffitt Cancer Center

9:30 AM - 9:32 AM AST

Introduction

Location: Ballroom B

Moderator: Sharee Umpierre, MD – University of Puerto Rico School of Medicine, University of Puerto Rico Comprehensive Cancer Center

Moderator: Robert Wenham, MD, MS – H. Lee Moffitt Cancer Center

9:32 AM - 9:38 AM AST

Rinatabart sesutecan (Rina-S) plus bevacizumab (BEV) for patients (pts) with recurrent ovarian cancer (OC): First disclosure from cohort D2 of the phase 1/2 RAINFOL-01 study

Location: Ballroom B

Speaker: Cara Mathews, MD – Women & Infants Hospital/Brown University

9:38 AM - 9:44 AM AST

Sacituzumab Tirumotecan (Sac-TMT) Plus Pembrolizumab Maintenance Therapy in Ovarian Cancer: Results From the Phase 2 2870-002/SKB264-II-06 Study

Location: Ballroom B

Speaker: Xiaohua Wu, MD, PhD – Oncology Department, Fudan University Shanghai Cancer Center

9:44 AM - 9:52 AM AST

Distillation

Location: Ballroom B

Speaker: Eugenia Girda, MD – Rutgers Cancer Institute

9:52 AM - 9:58 AM AST

Trastuzumab deruxtecan (T-DXd) for pretreated patients (pts) with HER2- expressing solid tumors: DESTINY-PanTumor02 (DP-02) Part 1 final analysis

Location: Ballroom B

Speaker: Vicky Makker, MD – Memorial Sloan Kettering Cancer Center

9:58 AM - 10:04 AM AST

A Multicenter, Open-Label, Phase I/II Study of IBI130, a TROP2-Targeting Antibody-Drug Conjugate, as Monotherapy in Patients with Recurrent or Metastatic Cervical Cancer

Location: Ballroom B

Speaker: Qin Xu, PhD – Fujian Cancer Hospital

10:04 AM - 10:12 AM AST

Distillation

Location: Ballroom B

Speaker: Robert Wenham, MD, MS – H. Lee Moffitt Cancer Center

10:12 AM - 10:30 AM AST

Q&A

Location: Ballroom B

9:30 AM - 10:30 AM AST
Focused Forum X: Genetics - Keeping up with the Genes

9:30 AM - 9:32 AM AST

Introduction

Location: 209

Moderator: Tiffany Sia, MD – Bay Area Gynecology Oncology

Moderator: Mae Zakhour, MD – Spectrum Health

9:32 AM - 9:38 AM AST

Age at ovarian cancer diagnosis varies by lynch syndrome gene: a genetic testing laboratory registry study

Location: 209

Speaker: Ying Liu, MD, MPH – Memorial Sloan Kettering Cancer Center

9:38 AM - 9:44 AM AST

Hormone Replacement Therapy Following Oophorrectomy and Breast Cancer Risk in BRCA Pathogenic Variant Carriers

Location: 209

Speaker: Shira Regev Sadeh, MD – Carmel Medical Center

9:44 AM - 9:50 AM AST

ACT-ON: Assisted Cascade Testing via Outreach and Navigation - Real-world experience with clinician-facilitated cascade testing

Location: 209

Speaker: Melissa Frey, MD, MS – Weill Cornell Medicine

9:50 AM - 9:58 AM AST

Distillation

Location: 209

Speaker: Andrea Hagemann, MD, MSCI – Washington University School of Medicine

9:58 AM - 10:04 AM AST

Impact of Concomitant Hysterectomy on Quality of Life in BRCA Pathogenic Variant Carriers Undergoing Risk-Reducing Salpingo-Oophorectomy

Location: 209

Speaker: Chen Nahshon, MD – Carmel Medical Center

10:04 AM - 10:10 AM AST

IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment): A Feasibility Randomized Trial

Location: 209

Speaker: Kirsten Jorgensen, MD – Vanderbilt University Medical Center

10:10 AM - 10:18 AM AST

Distillation

Location: 209

Speaker: Stephanie Blank, MD – Icahn School of Medicine at Mount Sinai

10:18 AM - 10:30 AM AST

Q&A

Location: 209

9:30 AM - 10:30 AM AST
Rapid-Fire Oral IV: Long-term Trial Outcomes

9:30 AM - 9:32 AM AST

Introduction

Location: 208

Moderator: David Cantu De Leon, MD, PHD – Instituto Nacional de Cancerologia

Moderator: Roisin O'Cearbhaill, MD – Memorial Sloan Kettering Cancer Center

9:32 AM - 9:35 AM AST

Patient-reported outcomes from the phase 3 ENGOT-ov65/KEYNOTE-B96 trial of pembrolizumab versus placebo plus paclitaxel, with or without bevacizumab, in platinum-resistant recurrent ovarian cancer

Location: 208

Speaker: Emese Zsiros, MD, PhD – Roswell Park Comprehensive Cancer Center

LBA

9:35 AM - 9:38 AM AST

Combination PP2A inhibition and PD-1 blockade with LB-100 and dostarlimab in ovarian clear cell carcinoma

Location: 208

Speaker: Helen Clark, MD – The University of Texas MD Anderson Cancer Center

LBA

9:38 AM - 9:41 AM AST

Immune-related adverse effects in gynecologic oncology patients on pembrolizumab: trial evidence vs real-world experience

Location: 208

Speaker: Ellery Sarosi, MD – University of Michigan

9:41 AM - 9:44 AM AST

Patient-reported outcomes from the final analysis of the PRIMA/ENGOT-OV26/GOG-3012 trial of niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: results from the homologous recombination-deficien

Location: 208

Speaker: Floor Backes, MD – The Ohio State University

9:44 AM - 9:47 AM AST

Effect of adjuvant treatment after secondary cytoreductive surgery in patients with recurrent granulosa cell tumor

Location: 208

Speaker: Elio Tahan, MD – MD Anderson Cancer Center

9:47 AM - 9:57 AM AST

Distillation

Location: 208

Speaker: Premal Thaker, MD – Washington University in St. Louis

9:57 AM - 10:02 AM AST

Q&A

Location: 208

10:02 AM - 10:05 AM AST

Beyond Sedlis: Validation of histology-specific risk factors for stage I cervical squamous cell carcinoma and adenocarcinoma

Location: 208

Speaker: Tullia Rushton, MD – Erlanger Hospital

10:05 AM - 10:08 AM AST

Phase 1b/2a randomized, double-blind study demonstrates potential of ABI-2280, a novel antiviral vaginal insert for the treatment of persistent high-risk/oncogenic HPV infection

Location: 208

Speaker: Warner Huh, MD, FCOG, FACS – University of Alabama at Birmingham

10:08 AM - 10:11 AM AST

Pathologic response to hypofractionation in locally advanced cervical cancer

Location: 208

Speaker: David Cantu De Leon, MD, PHD – Instituto Nacional de Cancerologia

10:11 AM - 10:14 AM AST

Prognostic significance of distant lymph node metastases alone in stage IVB cervical cancer

Location: 208

Speaker: Christian Dagher, MD MSc – Hospital of the University of Pennsylvania

10:14 AM - 10:24 AM AST

Distillation

Location: 208

Speaker: Dana Chase, MD – David Geffen School of Medicine at UCLA

10:24 AM - 10:30 AM AST

Q&A

Location: 208

9:30 AM - 10:30 AM AST
Workshop: Grassroots in Action: Members as Advocates, Protecting Patients, Protecting Practice: Advocacy Skills Every Gyn Onc Needs
Moderator: Emily Ko, MD, MSCR – University Of Pennsylvania

9:30 AM - 9:35 AM AST

Introduction

Location: 104

Moderator: Emily Ko, MD, MSCR – University Of Pennsylvania

9:35 AM - 9:40 AM AST

SGO Government Relations Accomplishments over the past 3 years: Committee Highlights

Location: 104

Speaker: Mark Shahin, MD, FACOG, FACS – Penn State Hershey Medical Center

9:40 AM - 9:48 AM AST

CRD Recorded Video

Location: 104

Speaker: Mark Shahin, MD, FACOG, FACS – Penn State Hershey Medical Center

9:48 AM - 9:58 AM AST

Advocacy Tools and Strategies

Location: 104

Speaker: Lindsay Ferguson, MD – Univerisity Hospitals Cleveland Medical Center

9:58 AM - 10:08 AM AST

From Intimidation to Influence

Location: 104

Speaker: Rana Aliani, MD – The University of Kansas Medical Center

10:08 AM - 10:22 AM AST

Hands-on: What would you do?

Location: 104

Speaker: Larissa Mattei, MD – UMass Memorial Health

Speaker: Jessica Hamilton

10:22 AM - 10:27 AM AST

From Session to Action: Your First Steps

Location: 104

Speaker: Emily Ko, MD, MSCR – University Of Pennsylvania

10:27 AM - 10:30 AM AST

Wrap-up and Closing

Location: 104

Moderator: Mark Shahin, MD, FACOG, FACS – Penn State Hershey Medical Center

10:30 AM - 10:45 AM AST
Transition Break

10:30 AM - 10:45 AM AST

Transition Break

10:45 AM - 11:15 AM AST
Business Meeting/Member Forum

10:45 AM - 11:15 AM AST

Business Meeting/Member Forum

Location: Exhibit Hall A

11:15 AM - 12:15 PM AST
Scientific Plenary V: Emerging Strategies in Cervical Cancer Care

11:15 AM - 12:15 PM AST

Scientific Plenary V: Emerging Strategies in Cervical Cancer Care

Location: Exhibit Hall A

11:15 AM - 11:17 AM AST

Introduction

Location: Ballroom A

Moderator: Charles Leath, III, MD, MSPH – University of Alabama at Birmingham

Moderator: Roberto Vargas, MD – The Cleveland Clinic

11:19 AM - 11:27 AM AST

Sacituzumab Tirumotecan (Sac-TMT) Plus Pembrolizumab in Participants With Recurrent or Metastatic Cervical Cancer: Results From the Phase 2 2870-002/SKB264-II-06 Study

Location: Exhibit Hall A

Speaker: Xiaohua Wu, MD, PhD – Oncology Department, Fudan University Shanghai Cancer Center

11:27 AM - 11:35 AM AST

Tisotumab vedotin in combination with carboplatin and pembrolizumab with or without bevacizumab in first-line recurrent or metastatic cervical cancer: first disclosure of arm H from the ENGOT-cx8/GOG-3024/innovaTV 205 study

Location: Exhibit Hall A

Speaker: Toon Van Gorp, MD, PhD – University Hospital Leuven, KU Leuven

11:35 AM - 11:43 AM AST

Development of ENG–Targeted CAR T cells for cervical cancer: Direct tumor targeting and microenvironment modulation

Location: Exhibit Hall A

Speaker: Min Guan, MD, PhD – City of Hope National Medical Center

11:43 AM - 11:51 AM AST

Exclusion of Individuals with HIV from Cervical Cancer Clinical Trials: Lack of Progress in the Immunotherapy Era

Location: Exhibit Hall A

Speaker: Lauren Gottshall, MD – Rutgers New Jersey Medical School

11:51 AM - 12:01 PM AST

Distillation

Location: Exhibit Hall A

Speaker: Ritu Salani, MD,MBA – University of California;Los Angeles

12:01 PM - 12:15 PM AST

Q&A

Location: Exhibit Hall A

12:15 PM - 12:30 PM AST
Closing Ceremony
Live Streamed

12:15 PM - 12:30 PM AST

Closing Ceremony

Location: Exhibit Hall A

Live Streamed